All roads lead to COPD… or not?
Our understanding of the pathogenesis of COPD has changed very significantly over the past few years.
Our understanding of the pathogenesis of COPD has changed very significantly over the past few years.
A new research paper was published on the cover of Aging (listed by MEDLINE/PubMed as «Aging (Albany NY)» and «Aging-US» by Web of Science) Volume 15, Issue 14, entitled, «Human senescent fibroblasts trigger progressive lung fibrosis in mice.»
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer.
The role of the immune response in the pathogenesis of idiopathic pulmonary fibrosis (IPF) remains controversial.
It is now well established that there are different life-long lung function trajectories in the general population, and that some are associated with better or worse health outcomes.
The Global Burden of Disease Study 2017 identified that a country’s sociodemographic index was a key factor affecting mortality and loss of health from respiratory diseases.
COPD is the elephant in the room for many patients with CVDs.
Chronic Obstructive Pulmonary Disease (COPD) is the third cause of death worldwide. While tobacco smoking is a key risk factor, COPD also occurs in never-smokers (NS).
1 year after an acute COVID-19 episode, patients with either lung sequelae or long COVID show a stronger SARS-CoV-2-specific T-cell response than fully recovered individuals, suggesting persistent cell stimulation by residual viral reservoirs
Chief Editor James Chalmers interviews Alvar Agusti (Hospital Clinic, Barcelona, Spain)about the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) report. Listen it here.